#0371
The use patient-derived prostate cancer organoids as a tool to predict response to therapy
O. Perera1, P. B Thomas2
1Department
of Urology, Princess Alexandra Hospital,, Brisbane, Australia
2Queensland Bladder Cancer Initiative (QBCI), School of Biomedical
Sciences, Queensland University of Technology (QUT), Princess Alexandra
Hospital, Brisbane, Australia
Introduction:
Prostate cancer is the 2 nd most commonly diagnosed cancer amongst Australian men. Whilst Prostate cancer is the 2 nd most commonly diagnosed cancer amongst Australian men. Whilst localised prostate cancer can be curatively treated with radiation or surgical resection, 10-20% of men present with metastatic disease. Individual patient responses to pharmacotherapy vary. We present a pipeline of deriving patient-derived organoids as a tool for predicting patient-centric responses to therapy.
Material and methods:
At the time of robotic assisted laparoscopic prostatectomy at the Princess Alexandra Hospital, patient tumour tissue, demographic data were collected. Utilising an organoid medium-Matrigel™ suspension, 3D in vitro cultures of patient-derived organoids (PDO) were developed. PDO growth and viability were inspected using time-lapse and fluorescence microscopy. PCa PDOs were treated with combinations of standard-of-care chemotherapies over a 6-day period; with endpoint viability measured to indicate response. Standard histology and immunohistochemistry were conducted on original patient tissue and PDOs to validate the prostatic origin.
Results:
To date, our tissue biobank contains, 23 malignant prostate tumours, 8 samples of benign prostate tissue and one benign lymph node. Fourteen patients had definitive histology demonstrating intermediate favourable disease (Gleason 3+4=7). The remainder of patients had intermediate unfavourable disease (Gleason 4+4=8). The vast majority of patients had acinar pattern adenocarcinoma, whereas two patients had mixed ductal-acinar adenocarcinoma and intraductal adenocarcinoma. In our cohort we were able to culture PDOs and conduct personalised drug screens, however the success of organoid generation was low.